Alexandra Shillingburg1, Lisa Biondo2. 1. Department of Clinical Pharmacy, West Virginia University Healthcare, Morgantown, West Virginia ; Alexander B. Osborn Hematopoietic Malignancy and Transplantation Program, Mary Babb Randolph Cancer Center, West Virginia University Healthcare, Morgantown, West Virginia. 2. Department of Clinical Pharmacy, West Virginia University Healthcare, Morgantown, West Virginia.
Abstract
OBJECTIVE: To describe the use of aprepitant and fosaprepitant, a neurokinin 1 (NK-1) receptor inhibitor, in children and adolescents at a large academic medical center, for the prevention and management of chemotherapy-induced nausea and vomiting (CINV). METHODS: A retrospective chart review was conducted using an electronic medical record system to evaluate the use of aprepitant and fosaprepitant in all pediatric patients that were discharged from a single academic medical center between February 25, 2009 and May 25, 2012. RESULTS: Twenty-six patients were included in this review and received a total of 287 doses over the span of 114 cycles. Mean age was 10.1 years, with a range of 11 months to 17 years old. In 16 of 26 patients, aprepitant was used as the primary prophylaxis. Of those patients who received primary prophylaxis, 6 of 16 received it for highly emetogenic chemotherapy, and 10 of 16 received it for moderately emetogenic chemotherapy. Intravenous fosaprepitant was used in 7 of 26 patients, ages 13 to 17 (median 14) years old. No adverse effects attributable to aprepitant were reported. CONCLUSIONS: Use of aprepitant and fosaprepitant in pediatric patients appeared to be well tolerated. No currently published reports data using aprepitant in a patient younger than 32 months old, whereas we reported its use in patients as young as 11 months old.
OBJECTIVE: To describe the use of aprepitant and fosaprepitant, a neurokinin 1 (NK-1) receptor inhibitor, in children and adolescents at a large academic medical center, for the prevention and management of chemotherapy-induced nausea and vomiting (CINV). METHODS: A retrospective chart review was conducted using an electronic medical record system to evaluate the use of aprepitant and fosaprepitant in all pediatric patients that were discharged from a single academic medical center between February 25, 2009 and May 25, 2012. RESULTS: Twenty-six patients were included in this review and received a total of 287 doses over the span of 114 cycles. Mean age was 10.1 years, with a range of 11 months to 17 years old. In 16 of 26 patients, aprepitant was used as the primary prophylaxis. Of those patients who received primary prophylaxis, 6 of 16 received it for highly emetogenic chemotherapy, and 10 of 16 received it for moderately emetogenic chemotherapy. Intravenous fosaprepitant was used in 7 of 26 patients, ages 13 to 17 (median 14) years old. No adverse effects attributable to aprepitant were reported. CONCLUSIONS: Use of aprepitant and fosaprepitant in pediatric patients appeared to be well tolerated. No currently published reports data using aprepitant in a patient younger than 32 months old, whereas we reported its use in patients as young as 11 months old.
Authors: Bernardo L Rapoport; Karin Jordan; Judith A Boice; Arlene Taylor; Carole Brown; James S Hardwick; Alexandra Carides; Timothy Webb; Hans-Joachim Schmoll Journal: Support Care Cancer Date: 2009-07-01 Impact factor: 3.603
Authors: Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544
Authors: P J Hesketh; S M Grunberg; J Herrstedt; R de Wit; R J Gralla; A D Carides; A Taylor; J K Evans; K J Horgan Journal: Support Care Cancer Date: 2006-02-01 Impact factor: 3.603
Authors: Lia Gore; Sant Chawla; Antonio Petrilli; Molly Hemenway; Debra Schissel; Vickey Chua; Alexandra D Carides; Arlene Taylor; Suzanne Devandry; Jack Valentine; Judith K Evans; Bettina Oxenius Journal: Pediatr Blood Cancer Date: 2009-02 Impact factor: 3.167
Authors: R M Navari; R R Reinhardt; R J Gralla; M G Kris; P J Hesketh; A Khojasteh; H Kindler; T H Grote; K Pendergrass; S M Grunberg; A D Carides; B J Gertz Journal: N Engl J Med Date: 1999-01-21 Impact factor: 91.245
Authors: Karin Melanie Cabanillas Stanchi; Martin Ebinger; Ulrike Hartmann; Manon Queudeville; Judith Feucht; Michael Ost; Marie-Sarah Koch; Carmen Malaval; Markus Mezger; Sarah Schober; Simone Weber; Sebastian Michaelis; Veit Lange; Peter Lang; Rupert Handgretinger; Michaela Döring Journal: Drug Des Devel Ther Date: 2019-09-30 Impact factor: 4.162
Authors: Karin Melanie Cabanillas Stanchi; Semjon Willier; Julia Vek; Patrick Schlegel; Manon Queudeville; Nora Rieflin; Veronika Klaus; Melanie Gansel; Joachim Vincent Rupprecht; Tim Flaadt; Vera Binder; Tobias Feuchtinger; Peter Lang; Rupert Handgretinger; Michaela Döring Journal: Drug Des Devel Ther Date: 2020-09-25 Impact factor: 4.162